Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Frederiksberg, Denmark Clinical Trials

A listing of Frederiksberg, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (79) clinical trials

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

Number of patients and target population: 114 patients with a diagnosis of alcohol dependence and 25 healthy participants (described later). The patients included in the trial will be treated for 26 weeks with once-weekly subcutaneous injection of Bydureon (exenatide) 2 mg or placebo. The medication will be provided as a ...

Phase

0.38 miles

Learn More »

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

This randomized double blind with double dummy technique phase 2a study will be run in 2-3 EU countries, most likely Sweden, Denmark and The Netherlands involving 5-6 sites. It is estimated that 80-100 patients have to be enrolled to ensure the randomization target of 40. The study population is patients ...

Phase

0.38 miles

Learn More »

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial

This is a single center, randomized (1:1, active : standard of care), controlled, open-label, investigator-initiated pilot phase IIa trial in patients with septic shock investigating the efficacy and safety of administrating OctaplasLG as compared to crystalloids, such as Ringer-Acetate (standard of care) in a total of 40 patients. 40 patients ...

Phase

1.73 miles

Learn More »

Effect of High-dose Naloxone Following Third Molar Extraction

Naloxone is a combined mu-opioid-receptor (MOR) inverse agonist and antagonist drug, which dose-dependently demonstrates hypoalgesic and hyperalgesic properties. Systemically administrated naloxone (3.0-10.0 mg/kg) and naltrexone (0.3-3.0 mg/kg) have been used in rodents to study the role of endogenous opioids on central processing of pain. It has been hypothesized that the ...

Phase

1.73 miles

Learn More »

Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis

The Primary endpoints of the study include: Safety and tolerability of velmanase alfa as per Adverse events (AEs, including IRR), vital signs, laboratory parameters (hematology, biochemistry and urinanalysis) Detection of anti-velmanase alfa antibodies and neutralizing/inhibitory antibodies The Secondary endpoints include changes from baseline to 24 months for the following parameters. ...

Phase

2.14 miles

Learn More »

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).

Phase

2.14 miles

Learn More »

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

Phase

2.14 miles

Learn More »

A Trial of Ibrutinib Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days. Patients with complete remission, partial response or stable disease will enter a maintenance phase with treatment with ...

Phase

2.14 miles

Learn More »

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide ...

Phase

2.14 miles

Learn More »

AZD9291 an Irreversible EGFR-TKI in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI Coupled to Extensive Translational Studies

This is a phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed following treatment with an approved epidermal growth factor tyrosine kinase inhibitor agent. If feasible, ...

Phase

2.14 miles

Learn More »